1. Home
  2. NNY vs PLX Comparison

NNY vs PLX Comparison

Compare NNY & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New York Municipal Value Fund

NNY

Nuveen New York Municipal Value Fund

HOLD

Current Price

$8.52

Market Cap

161.7M

Sector

Finance

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.79

Market Cap

230.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNY
PLX
Founded
1987
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
161.7M
230.0M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
NNY
PLX
Price
$8.52
$2.79
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
38.0K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$53,399,000.00
Revenue This Year
N/A
$9.67
Revenue Next Year
N/A
$23.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.77
$1.34
52 Week High
$8.94
$3.19

Technical Indicators

Market Signals
Indicator
NNY
PLX
Relative Strength Index (RSI) 45.50 50.71
Support Level $8.48 $2.59
Resistance Level $8.54 $3.03
Average True Range (ATR) 0.14 0.13
MACD -0.01 -0.05
Stochastic Oscillator 21.62 36.21

Price Performance

Historical Comparison
NNY
PLX

About NNY Nuveen New York Municipal Value Fund

Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: